Biogen expects to reduce headcount by 1,000 under $700M operational savings plan
Fresh off two FDA green lights — a full approval for Alzheimer’s and an accelerated nod in ALS — Biogen CEO Chris Viehbacher is bringing down the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
